Yoseph Shaaltiel, Executive VP, R&D at Protalix BioTherapeutics, Inc. (PLX), sold 380,000 shares at $7.08 ($2.7M) on 2010-03-24, disclosed to the SEC on 2010-03-25.
Scheduled sale ($2.7M) by Executive VP, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.02 | 127,300 | $894K | 33.4% |
| 2 | $7.08 | 202,700 | $1.4M | 53.6% |
| 3 | $7.00 | 50,000 | $350K | 13.1% |
| Total | $7.05 avg | 380,000 | $2.7M | 100% |
| Filing → |
| PLX | SELL | 2010-06-23 | $371K | — | Filing → |
| PLX | SELL | 2010-05-03 | $89K | — | Filing → |
| PLX | SELL | 2010-04-16 | $9K | — | Filing → |